NASDAQ:REPH
Delisted
Recro Pharma Stock News
$0.675
+0 (+0%)
At Close: Aug 17, 2022
Recro Pharma, Inc. (REPH) CEO David Enloe On Q4 2021 Results - Earnings Call Transcript
12:33am, Wednesday, 02'nd Mar 2022 Seeking Alpha
Recro Pharma GAAP EPS of $0.04 beats by $0.11, revenue of $22.3M beats by $0.89M
09:14pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Recro Pharma press release (REPH): Q4 GAAP EPS of $0.04 beats by $0.11.Revenue of $22.3M (+125.0% Y/Y) beats by $0.89M.
Recro Pharma GAAP EPS of -$0.04 beats by $0.03, revenue of $22.3M beats by $0.89M
09:13pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Recro Pharma press release (REPH): Q4 GAAP EPS of -$0.04 beats by $0.03.Revenue of $22.3M (+125.0% Y/Y) beats by $0.89M.
Recro Reports Fourth Quarter and Year End 2021 Financial Results
09:05pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million
Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
07:33pm, Tuesday, 01'st Mar 2022
Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
09:05pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
04:05pm, Tuesday, 22'nd Feb 2022
Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention
12:00pm, Wednesday, 26'th Jan 2022 GlobeNewswire Inc.
SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving com
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
12:00pm, Wednesday, 19'th Jan 2022 GlobeNewswire Inc.
Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
12:00pm, Monday, 03'rd Jan 2022 GlobeNewswire Inc.
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving comp
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
07:00am, Monday, 03'rd Jan 2022
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving comple
Recro Pharma, Inc. (NASDAQ:REPH) Major Shareholder Sells $32,600.00 in Stock
12:28pm, Saturday, 18'th Dec 2021 Dakota Financial News
Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Awm Investment Company, Inc. sold 20,000 shares of the companys stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $1.63, for a total value of $32,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed []
Zacks Investment Research Lowers Recro Pharma (NASDAQ:REPH) to Hold
10:18am, Saturday, 11'th Dec 2021 Dakota Financial News
Zacks Investment Research cut shares of Recro Pharma (NASDAQ:REPH) from a buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The []
Recro Pharma (NASDAQ:REPH) Rating Lowered to Hold at Zacks Investment Research
08:00am, Friday, 10'th Dec 2021 Transcript Daily
Recro Pharma (NASDAQ:REPH) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative []
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
01:50pm, Wednesday, 08'th Dec 2021 Zacks Investment Research
Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
